Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

20-year trends in hypoglycaemic episodes leading to hospitalisation

Severe hypoglycaemia rates in Denmark halve between 1998 and 2018, potentially as a result of new analogue insulins.

This study used data from the Danish National Patient Registry to assess trends in the rate of hospitalisation for hypoglycaemia, and predisposing factors and treatments, over the 20 years between 1998 and 2018. Among 44 297 people with type 1 diabetes in the cohort, there were 37 209 hospitalisations for hypoglycaemia. The incidence rate began at 8 per 100 person-years in 1998, peaked at 10 per 100 person-years in 2003 and fell steadily thereafter, reaching a low of 4 per 100 person-years in 2018.

Data on treatment were available for 18 031 people with type 1 diabetes, of whom 5521 were hospitalised for hypoglycaemia. Insulin analogues were associated with lower hypo rates compared with human insulins (both long-acting and fast-acting, as well as premixed), although the confidence intervals overlapped. The insulin analogues glargine and detemir were introduced in 2004, when hospitalisation rates began to fall.

The authors acknowledge a number of study limitations. Data on hospitalisations were used; however, these comprise only a fifth of severe hypoglycaemic episodes. The authors also only analysed the time to first hospitalisation for hypoglycaemia, and not recurrent episodes. Finally, the use of diabetes technology such as insulin pumps and continuous glucose monitoring, which would also have increased over the study period and are likely to have contributed to reduced hospitalisations, was not analysed. Nonetheless, the authors conclude that these safety findings are important and have implications for people on older insulin therapies.

Click here to read the study in full.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.